TNF and inflammatory bowel disease: Once released, the OMVs target to inflammatory macrophages and delivered Cas9 RNPs to disrupt TNF-α expression, resulting in marked alleviation of colitis symptoms in inflammatory bowel disease models (Lin et al., 2024).